Q-omics provides the consensus-scored ANKRD19P profile across patient tissues and cancer cell-line models. ANKRD19P expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ANKRD19P is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, ANKRD19P RNA expression shows 17,806 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, and THYM as cancer lineages where ANKRD19P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD19P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD19P survival associations across molecular data types. ANKRD19P RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD19P RNA expression–survival associations across cancer types. High ANKRD19P expression shows unfavorable associations in UVM, but favorable associations in HNSC, CESC, UCEC, LUSC and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for ANKRD19P RNA expression.
This table summarizes ANKRD19P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ANKRD19P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD19P shows higher tumor expression in HNSC, KIRC, BLCA, LIHC, BRCA and KIRP. The HNSC box plot shows higher ANKRD19P RNA expression in tumor versus normal tissue (log2 FC = +0.929, t-test p < 0.001).
This table shows molecular features associated with ANKRD19P in patient tissues and cancer cell lines. In patient samples, ANKRD19P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD19P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC.
